Timing, hosts and locations of (grouped) events of NanoImpactNet

More documents

Recommendations

Info

NanoSafetyCluster ‐ Compendium 2012 batches and identify the source of such variability. Strategies to reduce this variability will be developed. � JRA2 ‐ development of reliable labelling: A reliable strategy has been developed to isotopically label ZnO nanoparticles to allow for detection in in vivo experimental models; Fluorescently labelled nanoparticles are currently being synthesised and characterised. � JRA 3 ‐ Development and validation of characterisation tools for nanoparticles in situ: a protocol has been developed and refined for single particle Inductively coupled mass spectrometry (SP‐ICP‐MS); Training in the application of this protocol will be provided to JRA3 partners (and external researchers), and the protocol will be used to perform a round robin study to quantitatively assess the presence and composition of nanoparticles in complex organic mixtures. � JRA 4 ‐ Development of optimal modes of presentation of nanoparticles for quantitative reproducibility: A literature survey has been undertaken to identify the most widely used methods to present nanoparticles to in vitro cell systems; the most promising are being chosen as candidates for round robin testing in order to determine the method that produces the most reproducible and homogenous dose of nanoparticles across all cells in the culture. Effect of cell division / cell cycle on dose and uptake of nanoparticles is also being assessed. � JRA 5 ‐ Towards development of alternative in vitro tests: This WP is scheduled to commence research activities in February 2012. JRA 5 has secured a session at the ESOF 2012 (European Science Open Forum conference (11‐15 July, 2012, Dublin) http://www.dublinscience2012.ie/. The session is entitled ‘What realistic alternatives are there to animal testing to ensure safe introduction of new technologies?’ and will be a panel discussion targeted at scientists, policy makers and industry. The session is part of ESOF 2012 Theme 5. Science: Reshaping the frontiers of knowledge. � The vision of QNano is thus a unified and continuous flow of knowledge and information, from discovery to implementation and dissemination, enhancing the overall access, and service available to the research community (the Users), and raising the quality of the research outputs from the whole field. 6 Next steps and how to get involved in QNano Year 2 will be an exciting one for QNano, with the first Transnational Access Users undertaking their research visits at the various partner facilities, with two additional transnational Access calls planned (opening 1st May 2012 and 1st November 2012). Additionally, there is an exciting schedule of theoretical and hands‐on (laboratory) training events for young researchers, as well as events to engage with and assess the needs of industry with regards to nanomaterials safety assessment. Results will begin to emerge from many of the JRA WPs, and every effort will be made to disseminate this to the relevant stakeholder communities in an appropriate manner. There are a number of ways that researchers and other stakeholders can get involved in QNano, including: � TA for researchers (must be Transnational), which can also include industry researchers, as long as there is some published output from the funded research visit which acknowledges the funding from QNano; � Via the Expert Resource Group which are external advisory groups supporting QNano in terms of activities. Expert groups on Toxicology, Eco‐toxicology, Alternative methods (in vitro), Biological Methods, and to promote engagement within ongoing international efforts in Regulation, Standardisation and other International issues (e.g. databases); � Via identification of training needs / support for development of training events to address gaps; � Via RR processes on specific topics / protocol development / testing / nomination of nanomaterials etc.; � Via participation in User Selection panels. Members and stakeholders from the nanosafety and nanomedicine communities are invited to participate in these activities, and can express their interest in this via an initial email to the QNano project office (project‐office@qnano‐ri.eu) who will forward your details to the relevant persons depending on where you wish to contribute. 250 Compendium of Projects in the European NanoSafety Cluster
7 References 1. Nanotechnology Market Forecast to 2013, RNCOS, May 1, 2009, Pub ID: CICQ2230088. 2. Roadmaps in Nanomedicine, Report from the European Commission /ETP Nanomedicine. http://www.etp‐nanomedicine.eu/public/press‐documents /publications/091022_ETPN_Report_2009.pdf NanoSafetyCluster ‐ Compendium 2012 3. The EU 6th Research Framework Programme (2002‐2006) devoted over €1.3 billion to nanotechnology and new materials, and has allocated € 3.5 billion to the NMP theme for the period 2009‐2013 (FP7). 4. Foss Hansen S, Maynard A, Baun A, Tickner JA. Late lessons from early warnings for nanotechnology. Nat Nanotechnol. 2008 Aug;3(8):444‐7. 5. http://www.nature.com/news/2009/090818/full/460937a.html 6. ISO/IEC Guide 43‐1, Proficiency testing by interlaboratory comparisons – Part 1: Development and operation of proficiency testing schemes, 2nd edition, 1997. 7. Dawson KA, Anguissola S, Lynch I. The need for in situ characterisation in nanosafety assessment: Transnational Access via the QNano research infrastructure. Nanotoxicology, 2012, in press. 8 Directory Table 1 Directory of people involved in the QNano project as beneficiaries* 1 . First Name Last Name Affiliation Address e‐mail Olivier Aguerre‐Chariol Institut National de L’Environnement et des Risques Ineris Rob Aitken Institute of Occupational Medicine Sergio Anguissola National University of Ireland, Dublin / University College Dublin Markus Berges Institut für Arbeitsschutz der Deutschen Gesetzlichen Unfallversicherung John Boland The Provost Fellows & Scholars of the College of the Holy and Undivided Trinity of Queen Elizabeth neat Dublin [Trinity College Dublin] Flemming Cassee Rijiksinstituut voor Volksgezondheid en Milieu Kenneth Dawson National University of Ireland, Dublin / University College Dublin Maria Dusinska Norsk institutt for luftforskning [Norwegian Institute for Air Research] Parc Technologique Alata Verneuil en Halatte 60550 France Research Park North / Riccarton UK‐EH14 4AP Edinburgh United Kingdom Belfield Dublin 4 Ireland Alte Heerstrasse 111 DE‐53757 Sankt Augustin Germany CRANN Trinity College Dublin Dublin 2 Ireland RIVM PO Box 1 3720 BA Bilthoven The Netherlands Belfield IE‐4 Dublin Ireland P.O.Box 100, Instituttveien 18 NO‐2027 Kjeller Norway 1 Note there are also additional partners who are non‐funded who are not included here. olivier.aguerre.chariol@ineris.fr rob.aitken@iom‐world.org sergio.anguissola@cbni.ucd.ie Markus.Berges@dguv.de jboland@tcd.ie Flemming.cassee@rivm.nl kenneth.a.dawson@cbni.ucd.ie maria.dusinska@nilu.no Compendium of Projects in the European NanoSafety Cluster 251
Page 1:
Compendium of Projects in the Europ
Page 5 and 6:
EDITED BY Michael Riediker, PD Dr.s
Page 7 and 8:
CONTENTS NanoSafetyCluster - Compen
Page 9 and 10:
Project Acronym ENNSATOX ENPRA EURO
Page 11 and 12:
Foreword NanoSafetyCluster - Compen
Page 13 and 14:
ENNSATOX ENgineered Nanoparticle Im
Page 15 and 16:
The biological membrane and its dep
Page 17 and 18:
distinguishes between the interacti
Page 19 and 20:
Figure 10. Schematic representation
Page 21 and 22:
WP5: • Permeability of NPs in hyd
Page 23 and 24:
NanoSafetyCluster - Compendium 2012
Page 25 and 26:
ENPRA RISK ASSESSMENT OF ENGINEERED
Page 27 and 28:
vitro findings with in vivo models;
Page 29 and 30:
protocols with real biological samp
Page 31 and 32:
and it was organised in the frame o
Page 33 and 34:
First Name Last Name Affiliation Ad
Page 35 and 36:
Page 37 and 38:
EURO-NanoTox European Center for Na
Page 39 and 40:
silver nanoparticles, iron nanopart
Page 41 and 42:
The core functions of the Center, h
Page 43 and 44:
8 Directory Table 1 Directory of pe
Page 45 and 46:
HINAMOX Health Impact of Engineered
Page 47 and 48:
High Resolution Electron Microscopy
Page 49 and 50:
integrated risk assessment. Integra
Page 51 and 52:
powders: What is the difference in
Page 53 and 54:
Page 55 and 56:
Page 57 and 58:
InLiveTox Intestinal, Liver and End
Page 59 and 60:
- to develop and validate a novel m
Page 61 and 62:
environments, IEEE Industrial Elect
Page 63 and 64:
INSTANT Innovative Sensor for the f
Page 65 and 66:
complementary research which will l
Page 67 and 68:
7 Copyright NanoSafetyCluster - Com
Page 69 and 70:
ITS-NANO Intelligent testing strate
Page 71 and 72:
approach to conveying the appropria
Page 73 and 74:
in the discussion. The integration
Page 75 and 76:
MARINA MANAGING RISKS of NANOMATERI
Page 77 and 78:
for risk analysis, these tools need
Page 79 and 80:
environmental ENM toxicity, but tox
Page 81 and 82:
propose it as a Method Validation F
Page 83 and 84:
and SiO2-NM200 and NM203, and a SiO
Page 85 and 86:
ModNanoTox Modelling nanoparticle t
Page 87 and 88:
3) To model environmental exposure
Page 89 and 90:
Nanodetector European Network on th
Page 91 and 92:
measurement interval. Measurements
Page 93 and 94:
5 Directory Table 1 Directory of pe
Page 95 and 96:
NANODEVICE Novel Concepts, Methods,
Page 97 and 98:
ENP in order to be sure of their sa
Page 99 and 100:
4.3 Exploring the association betwe
Page 101 and 102:
Page 103 and 104:
NanoFATE Nanoparticle Fate Assessme
Page 105 and 106:
or proteins associated with particu
Page 107 and 108:
sludge. Information on rates of slu
Page 109 and 110:
The exposures to be conducted will
Page 111:
NanoFATE progression beyond the “
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211: NanoSafetyCluster - Compendium 2012
Page 252 and 253: NanoSafetyCluster ‐ Compendium 20
Page 288: NanoSafetyCluster - Compendium 2012
show all

Timing, hosts and locations of (grouped) events of NanoImpactNet

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?